TECPR1 is activated by damage-induced sphingomyelin exposure to mediate noncanonical autophagy.

Autor: Kaur N; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., de la Ballina LR; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Haukaas HS; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Torgersen ML; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Radulovic M; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Munson MJ; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sabirsh A; Advanced Drug Delivery, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Stenmark H; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Simonsen A; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Carlsson SR; Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden., Lystad AH; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Publikováno v: The EMBO journal [EMBO J] 2023 Sep 04; Vol. 42 (17), pp. e113105. Date of Electronic Publication: 2023 Jul 06.